Fluoroquinolone Prophylaxis during Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia – Pros and Cons
Acta Haematologica · 2024 · 147 (2) · 186-197
DOI: 10.1159/000535119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 21.11.2023. Verfasst von Tomer Hoffman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Neutropenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background: Prophylaxis with fluoroquinolones (FQ) is commonly used in patients with acute leukemia (AL) during neutropenia. This practice is supported by an older meta-analysis reporting reduced mortality using FQ prophylaxis. Later meta-analyses have failed to reproduce this finding, presumably due to higher background FQ resistance rates limiting their effectiveness. Summary: This article reviews the pros and cons of FQ prophylaxis mainly in patients with AL. Most current guidelines do not support universal prophylaxis but rather recommend a selective approach, weighing the benefits against the risks. This recommendation is based on the lack of mortality benefit reported in more recent meta-analyses. FQ prophylaxis was demonstrated to reduce bacteremia and febrile neutropenia episodes, although mostly in trials performed in low-resistance settings (<20%), whereas current FQ resistance rates may reach 30–60%. Other disadvantages of FQ include potential adverse events, antibiotic resistance development, cost, increase in Gram-positive infections and resistant Gram-negative infections following prophylaxis, Clostridioides difficile infection, and an effect on gut microbiota. Key Messages: Taking the above into consideration, alternative approaches other than universal FQ prophylaxis should be considered. Centers with high FQ resistance rates may consider either withholding prophylaxis or providing selective prophylaxis for high-risk patients screened negative for FQ-resistant bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel.
- Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
- Hematology Division, Sheba Medical Center, Ramat Gan, Israel.
Zitieren
APA
Hoffman, T., Atamna, A., Litchevsky, V., Amitai, I., & Yahav, D. (2024). Fluoroquinolone Prophylaxis during Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia – Pros and Cons. Acta Haematologica, 147(2), 186-197. https://doi.org/10.1159/000535119
Vancouver
Hoffman T, Atamna A, Litchevsky V, Amitai I, Yahav D. Fluoroquinolone Prophylaxis during Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia – Pros and Cons. Acta Haematologica. 2024;147(2):186-197. doi:10.1159/000535119
BibTeX
@article{Hoffman2024,
author = {Hoffman, Tomer and Atamna, Alaa and Litchevsky, Vladislav and Amitai, Irina and Yahav, Dafna},
title = {Fluoroquinolone Prophylaxis during Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia – Pros and Cons},
journal = {Acta Haematologica},
year = {2024},
volume = {147},
number = {2},
pages = {186--197},
doi = {10.1159/000535119}
}
EUVIMED